Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020


	September 30, 2020	September 30, 2019
	(unaudited)	(unaudited)
Common Stock Warrants	2,772,117	2,716,300
Employee Stock Options	246,893	180,212
Preferred Stock	852,500	852,500
Total Shares of Common Stock Issuable	3,871,510	3,749,012

The below table represents the changes in the Company’s contract liabilities:


	Nine Months
	Ended
	September 30,
	2019
Revenue recognized in the period from:
Amounts included in contract liability at the beginning of the period	$	2,686,000